AMGN.NASDAQAmgen INC

Form 4: Amgen SVP Derek Miller Reports Stock Disposition

Sentiment:

Statement of Changes in Beneficial Ownership


Amgen Inc. SVP of Human Resources Derek Miller disposed of 151 shares of common stock to cover tax obligations.

Summary

  • Derek Miller, SVP of Human Resources at Amgen Inc., disposed of 151 shares of common stock.
  • The transaction occurred on May 7, 2026, at a price of $331.11 per share.
  • The disposition was executed to satisfy tax withholding obligations related to the vesting of equity awards.
  • Following this transaction, the reporting person maintains beneficial ownership of 12,444 shares of Amgen common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a strategic shift or market-driven sale.

Positives

  • The transaction is a routine administrative action related to tax withholding rather than a discretionary sale of shares.

Negatives

  • Reduction in the total number of shares held directly by a senior executive.

Risks

  • None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Future Outlook

Not applicable; this is a historical disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that routine tax-related share dispositions by corporate executives are standard industry practice and generally do not signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

  • The transaction aligns with standard executive compensation practices observed in large-cap biotechnology firms where equity vesting triggers mandatory tax withholding.

Stakeholder Impact

  • Minimal impact on shareholders as the transaction was a non-discretionary tax withholding event.

Key Dates

DateDescription
05/07/2026Date of the reported stock disposition transaction.
05/11/2026Date the Form 4 was signed and filed.

Keywords

Amgen, AMGN, Insider Trading, Form 4, Executive Compensation, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.